SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd ($INDO) is a top trending energy stock as escalating geopolitical tensions in the Middle East, including reported strikes on oil infrastructure and fears of supply disruption, fuel community speculation about its potential for a major rally, despite active profit-taking and volatility.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is trending as escalating Middle East tensions drive up oil prices, with the community actively discussing its substantial price action and anticipating a significant short squeeze due to high borrow rates and minimal shares available to short.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is seeing extreme volatility and a major sell-off following a Raymond James downgrade, fueled by the U.S. Space Force's decision to re-compete the critical $1.4 billion SCAR program, leaving the community debating whether the contract is lost or merely undergoing renegotiation for this drone defense leader.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is a central topic of discussion amid rising geopolitical tensions and the US Army's "Drone Dominance Program," with the community actively speculating on unprecedented demand for its drone and robotic solutions. Recent institutional boosts and public endorsements from military figures are fueling excitement for potential significant government contracts.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp. is trending as escalating geopolitical tensions are amplifying urgent discussions around domestic critical mineral supply chains for military munitions. The community is highlighting UAMY's unique position as the only US antimony producer, anticipating government contracts and funding to secure this vital resource amidst global supply pressures.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as recent weaker operating earnings and a substantial cash pile fuel community debate over whether the leadership transition to Greg Abel signals a shift towards more active capital deployment or if the conglomerate risks its "safe haven" reputation amidst market volatility.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as escalating Middle East tensions, including a halt in Qatar's LNG production, drive a sharp rise in global natural gas prices, favorably positioning the company's significant spot market exposure and rapidly expanding capacity. The community remains bullish, actively discussing its long-term value and project milestones like CP2, often viewing recent analyst downgrades as attempts to acquire cheaper shares.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Speculation is rampant around POET Technologies as NVIDIA's increasing focus on optical interconnects for AI data centers and Marvell's acquisition of Celestial AI validate the photonics sector, with the community anticipating significant partnership announcements and a revenue ramp, potentially coinciding with the upcoming OFC conference.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is seeing significant upward momentum driven by intense anticipation for its Phase 3 REGAL trial results for the cancer therapy GPS, which many in the community believe will show overwhelming efficacy due to the extended trial duration. This sentiment, combined with strong speculation of an imminent short squeeze and a potential buyout by a major pharmaceutical firm, is fueling a fierce battle around the $5 price level.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after delivering a strong Q4 earnings beat and optimistic 2026 revenue guidance, significantly amplified by a competitor's FDA rejection for a Cushing's syndrome drug, which positions Recorlev for expanded market leadership. Despite an apparent market overreaction, the community sees this as a prime buying opportunity given the company's high gross margins, path to profitability, and advancing blockbuster pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Zen Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to Hold

Wall Street Zen upgraded shares of Iovance Biotherapeutics from a "sell" rating to a "hold" rating in a report on Saturday...

Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?

Here is how Aldeyra Therapeutics, Inc. (ALDX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.

Brokers Set Expectations for IOVA Q1 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for Iovance Biotherapeutics in a research report issued to clients and...

Barclays Boosts Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $11.00

Barclays upped their target price on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an "overweight" rating in a report on Wednesday...

IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress

Iovance posts narrower Q4 loss as Amtagvi sales jump 33%. Shares soar on 50% ORR data and plans for registrational sarcoma study.

Iovance Biotherapeutics (NASDAQ:IOVA) Sees Strong Trading Volume Following Earnings Beat

Iovance Biotherapeutics (NASDAQ:IOVA) Sees Large Volume Increase on Strong Earnings...

Chardan Capital Has Lowered Expectations for Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price

Chardan Capital lowered their target price on shares of Iovance Biotherapeutics from $17.00 to $16.00 and set a "buy" rating on the stock in a research note on Wednesday...

Iovance Biotherapeutics (NASDAQ:IOVA) Raised to Market Outperform at Citizens Jmp

Citizens Jmp upgraded Iovance Biotherapeutics from a "market perform" rating to a "market outperform" rating and set a $5.00 price target on the stock in a research report on Wednesday...

<ul class="summary-bullets"><li>Chardan reiterated a ‘Buy’ rating and sees 323% upside, despite trimming its price target to $16 from $17.</li><li>Q4 margins hit a record high, with gross margin climbing to 50% from 43% in Q3, which the interim CEO said was Iovance’s “best ever” performance.</li><li>Pipeline momentum strengthened, with FDA Fast Track designation for Lifileucel in nonsquamous lung cancer.</li></ul>Shares of Iovance Biotherapeutics, Inc. (IOVA) posted their best session in two years on Tuesday after the company reported record fourth-quarter (Q4) margins, with investor sentiment buoyed by an analyst rating that implied more than 300% upside from current levels.<a href="https://stocktwits.com/symbol/IOVA">IOVA stock</a> jumped over 30% to $3.78 in Tuesday’s regular session, and added another 0.7% in extended trading.&nbsp;&nbsp;<h2 class="st-heading-2">Chardan Sees Huge Upside For IOVA</h2>On Tuesday, Chardan lowered its price target on Iovance to $16 from $17, implying a 323% upside from current levels, while retaining a ‘Buy’ rating.&nbsp;The brokerage attributed the Q4 margin rise to operational optimization and said further improvements are expected through 2026 as the company internalizes manufacturing of Lifileucel, its immune cell therapy for solid tumors, at its iCTC facility and optimizes research and development spending. It added that Iovance’s pipeline continues to advance, with early data in soft tissue sarcomas “looking encouraging.”<h2 class="st-heading-2">Amtagvi Drives Strong Q4 Revenue Surge</h2>Iovance reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-iova-stock-gain-pre-market-today/cZRvxIHR4Cc">Q4 revenue</a> of $86.7 million, beating analyst expectations of $81 million, while posting a Q4 loss of $0.18 per share, in line with estimates.Q4 total product revenue rose about 30% from the previous quarter to $87 million, led by about $65 million in U.S. Amtagvi revenue, a cell-based therapy for advanced melanoma, and $22 million from global Proleukin sales, a drug that helps activate the immune system during treatment.Gross margin from cost of sales climbed to 50%, up from 43% in the prior quarter, marking the company’s “best ever” margin performance, according to interim CEO Frederick Vogt, as said on the earnings call.For full-year 2025, Iovance reported total product revenue of about $264 million, coming in within its guidance range of $250 million to $300 million. The company ended the year with $303 million in cash, which is expected to fund operations into the third quarter of 2027.<h2 class="st-heading-2">CEO Sees “Remarkable” Revenue Growth In 2026</h2>Vogt said Iovance achieved its 2025 guidance range in its first full year of commercial launch, driven by rising demand for Amtagvi. On the earnings call, he said the company expects “remarkable revenue growth” in 2026 and sees potential for Amtagvi and Proleukin to generate more than $1 billion in peak U.S. sales.The company noted Amtagvi’s approval in Canada and pending regulatory decisions in the U.K. and Australia in the first half of 2026, with Switzerland targeted for the first half of 2027. Iovance is also working with European regulators to resubmit a marketing authorization application in 2026.<h2 class="st-heading-2">FDA Fast Track Granted For Lifileucel In Lung Cancer</h2>Iovance said Lifileucel has received Fast Track Designation from the FDA for previously treated nonsquamous non-small cell lung cancer, with interim data showing a 26% objective response rate and durability extending beyond 25 months. The company expects to complete enrollment in 2026 and to target an accelerated launch in the second half of 2027.Separately, the company announced positive early data in advanced soft-tissue sarcomas, where Lifileucel delivered a 50% confirmed response rate in an initial cohort of heavily pretreated patients. Iovance plans to initiate a single-arm registrational trial in the second quarter of 2026 and engage with regulators on an accelerated approval pathway.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IOVA was ‘extremely bullish’ amid a 550% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/iova_ss_png_a21e8bee3a.webp" alt="iova ss.png" width="970" height="142"><figcaption>IOVA sentiment and message volume as of February 25 | Source: Stocktwits</figcaption></figure>One user said, “potentially this could help Q1 margins go up further. If they can reach somewhere around 60%, it’ll be great progress towards profitability.”<stembedurl>https://stocktwits.com/ap20190829/message/645806810</stembedurl>Another user said, “THIS IS A 10/ share stock no doubt. You still have time to get it and make hay.”<stembedurl>https://stocktwits.com/ScottyG305/message/645801421</stembedurl>IOVA stock has surged 38% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the IOVANCE BIOTHERAPEUTICS logo is displayed on the screen of a tablet computer. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why

Shares of Iovance Biotherapeutics, Inc. (IOVA) posted their best session in two years on Tuesday after the company reported record fourth-quarter (Q4) margins

Equity

Chardan cited operational efficiencies and expected margin lift as Lifileucel manufacturing is fully internalized.

Top Penny Stocks To Add to Your Watchlist - February 24th

Larimar Therapeutics, Iovance Biotherapeutics, and Mana Capital Acquisition are the three Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced...

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

Stocktwits

MongoDB Inc

Stocktwits Polls

Traders are keenly awaiting 2026 revenue guidance, with management delaying its release to gather more data, hinting at "remarkable growth" ahead following Q4's 30% revenue jump.

Anticipation builds for new clinical data, including sarcoma's 50% ORR and NSCLC Fast Track designation, positioning TIL therapy as a potential oncology paradigm shift.

Elevated short interest combined with the stock's recent resilience is sparking speculation about a potential short squeeze, driving price targets higher.

Investors are closely scrutinizing management's communication and strategy, especially regarding guidance timing and the impact of recent executive appointments.

IOVA
Iovance Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IOVA News

IOVAIovance Biotherapeutics Inc